Sun Pharmaceutical Industries Limited Fundamentals

    Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures and markets branded and generic dosage forms and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations for a variety of treatment areas including central nervous system, dermatology, cardiovascular system, oncology and ophthalmology, neuropsychiatry, gastroenterology, anti-infective drugs, diabetes, pain relief / pain relief, vitamins / minerals / nutrients, respiratory, gynecology, urology ophthalmology, orthopedics, nephrology, dentistry, and other fields also provide APIs for anticancer drugs, peptides, steroids, sex hormones and controlled substances, and over-the-counter products. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

    Business area of the Company

    The company is one of the largest specialized generic pharmaceutical companies and the largest pharmaceutical company in India. Your vertically integrated business and skilled team enable you to offer high quality products that are trusted by customers and patients around the world at an affordable price.


    • Formulations
    • Active Pharmaceutical Ingredients - Crams
    • OTC


    • 2005:  Dilip Shanghvi is named Entrepreneur of the Year (Healthcare and Life Science) Ernst & Young.
    • 2007: Dilip Shanghvi is recognised as First Generation Entrepreneur of the Year CNBC-TV18.
    • 2007: Dilip Shanghvi wins Pharmaceutical Companies IMC Juran Quality Medal IMC Ramkrishna Bajaj National Quality Award Trust.
    • 2008: Sun Pharma wins Outstanding Exporter of the Year: Pharmaceuticals, Healthcare and Lifesciences Award CNBC TV 18:The International Trade Awards.
    • 2008: Sun Pharma receives Business Leadership Award NDTV Profit.
    • 2008: Dilip Shanghvi is named CEO of the Year Business Standard.
    • 2008: Dilip Shanghvi is honoured with Entrepreneur of the Year Award The Economic Times.
    • 2009: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
    • 2009: Sun Pharma receives Rolta Corporate Award: Pharmaceuticals Dun & Bradstreet.
    • 2010: Dilip Shanghvi receives Entrepreneur of the Year Award Ernst & Young.
    • 2010: Sun Pharma receives Business Leadership of the Year Award NDTV PROFIT.
    • 2011: Dilip Shanghvi is recognised as World Entrepreneur of the Year Ernst & Young.
    • 2011: Dilip Shanghvi is honoured with Businessman of the Year Award Business India.
    • 2011: Dilip Shanghvi is named Indian of the Year (Business) CNN IBN.
    • 2011: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
    • 2011: Sun Pharma is hailed as the Pharmaceutical Company of the Year Frost & Sullivan India Healthcare Excellence Awards.
    • 2012: Sun Pharma is named Most Outstanding Company of the Year CNBC-TV18 India Business Leader Awards.
    • 2012: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
    • 2012: Sun Pharma is listed in Asia''s Fab 50 Companies Forbes.
    • 2012: Sun Pharma wins Business Leadership of the Year - Pharmaceutical Award NDTV Profit.
    • 2013: Uday Baldota receives Best CFO in Pharma and Healthcare Award CNBC TV-18 CFO Awards.
    • 2013: Sun Pharma is named Company of the Year The Economic Times.
    • 2013: Sun Pharma is named Company of the Year Business Standard.
    • 2013: Sun Pharma is listed among Asia''s Fab 50 Companies Forbes.
    • 2014: Dilip Shanghvi receives Entrepreneur of the Year Award Forbes Magazine.
    • 2014: Sun Pharma receives Cardiovascular Pharmaceutical Company of the Year Award Frost & Sullivan India Healthcare Excellence Awards.
    • 2014: Dilip Shanghvi receives Business Leader of the Year Award The Economic Times.
    • 2014: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
    • 2014: Dilip Shanghvi receives JRD TATA Corporate Leadership Award All India Management Association.
    • 2015: Dilip Shanghvi receives Business Leader of the Year Award NDTV.
    • 2015: Sun Pharma receives Excellence in CSR Award “India Pharma Awards - 2015” instituted by UBM-India.
    • 2015: Sun Pharma receives India Pharma Research & Development Award 2015 Ministry of Chemicals & Fertilizers, Government of India.
    • 2016: Sun Pharmaceutical Industries Inc. receives DIANA (Distribution Industry Award for Notable Achievements) Award Healthcare Distribution Alliance, USA.
    • 2016: Dilip Shanghvi receives Padma Shri Award Government of India.
    • 2016: Sun Pharma receives Community Care Award ASSOCHAM (Associated Chambers of Commerce).
    • 2017: Dilip Shanghvi receives Entrepreneur of the Year Award All India Management Association (AIMA).
    • 2018: Dilip Shanghvi receives Lifetime Outstanding Achievement Award Indore Management Association (IMA).
    • 2018: Sun Pharma receives Outstanding Contribution in CSR Federation of Gujarat Industries.
    • 2018: Sun Pharma receives Best CSR Practices The Economic Times (ET).


    Establishment & Growth

    1983: The Company established with five psychiatry products and a two person marketing team
    1994: The Company lunches IPO
    1996: The Company expands sales network across 24 countries.
    2007: The Company demerges Sun Pharma Advanced Research Company (SPARC) into a separate entity becoming the first pure research company to be listed on India Stock Exchanges.
    2013: Ranbaxy acquisition catapults Sun Pharma to world’s 5th largest specialty generic pharmaceutical company.

    Acquisitions & Alliances

    1996: The Company acquires API plant from Knoll Pharma at Ahmednagar, Maharashtra, India.
    1997: The Company purchases equity stakes in TDPL and MJ Pharma.
    1997: The Company’s first international acquisition of Caraco Pharmaceutical Laboratories, USA.
    1999: The Company acquires Milmet Labs and Gujrat Lyka Organics, India.
    2000: The Company acquires Pradeep Drug Company, India.
    2004: The Company acquires Phlox Pharma (India) and niche brands from Women’s First Healthcare (US).
    2005: The Company completes buyout of manufatruing unit in Bryan, Ohio, US.
    2005: The Company acquires ICN’s business in Hungary from Valent Pharma.
    2005: The Company acquires intellectual property and assets of Able Labs from US District Bankruptcy court in New Jersey.
    2008: The Company acquires Chattem Chemicals Inc, US.
    2010: The Company acquires controlling stake in Israel-based Taro Pharmaceuticals, USA to effectively double company’s US businesses.
    2012: The Company completes two more acquisitions in USA; Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals.
    2014: The Company acquires Ranbaxy in a $4 billion landmark transaction to create world’s fifth largest specialty generic pharma company.
    2014: The Company acquires pharmalucence in USA.
    2015: The Company acquires GSK’s Opiates business in Australia
    2015: The Company acquires Insite Vision Inc. to strighthen branded ophthalmic portfolio in USA.
    2016: Sun Pharma acquires 14 brands from Novartis in Japan
    2016: Sun Pharma acquires Ocular Technologies, Sarl to strengthen branded ophthalmic portfolio
    2016: Sun Pharma acquires branded oncology product Odomzo (sonidegib) from Novartis for global markets
    2016: Sun Pharma acquires Biosintez to enhance presence in Russian market.

    Research & Manufacturing

    1983:Sun Pharma sets up compact manufacturing facility for tablets and capsules at Vapi, Gujarat
    1991: Sun Pharma establishes first research centre to create a base for strong product and process development
    1991: Ranbaxy establishes state-of-the-art manufacturing facility for Cephalosporins at Mohali, Punjab, India
    1995: Sun Pharma begins production at API manufacturing plant in Panoli, Gujarat, India.
    1997: Sun Pharma establishes new research facility in Mumbai, India
    1998: Sun Pharma begins operations at a new formulation unit in Silvassa, Gujarat, India
    2001: Sun Pharma commences production at new formulations unit in Dadra, India
    2004: Sun Pharma sets up new formulation unit in Jammu, India
    2004: Sun Pharma commissions first joint venture manufacturing unit in Dhaka, Bangladesh
    2015: Sun Pharma enters into research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies
    2016: International Centre for Genetic Engineering and Biotechnology (ICGEB) & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue
    2017: Sun Pharma & National Institute of Virology (NIV), India sign agreement to fight Zika, Chikungunya and Dengue.

    Products & Innovations

    1987: Sun Pharma begins sale of products across India
    1988: Sun Pharma launches Monotrate and Angizem, first cardiology products that are sold till today
    1989: Sun Pharma introduces gastroenterology products in India
    1998: Sun Pharma acquires a basket of products from Natco Pharma
    2014: Sun Pharma and Merck & Co. Inc. enter into licensing agreement for Tildrakizumab (MK-3222)
    2016: Sun Pharma launches Imatinib Mesylate in USA
    2016: Sun Pharma launches first branded ophthalmic product, BromSite in USA.

    Sun Pharmaceutical Industries Limited Stock Price Analysis and Quick Research Report

    Let’s scrutinize however Sunpharma is acting and if it's the proper time to buy the stock of Sunpharma with careful analysis.

    Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1,737.25 Cr.
    Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.27 , which is a strong indication for the company.
    EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was -33.37 % which is bad for the company.
    Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 22.84 % which is a good sign for profitability.
    ROE: Sun Pharma Inds. have a poor ROE of 8.66 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.


    SUNPHARMA Mini Live Chart

    SUNPHARMA Technicals 

    NOTE: We might update this page with latest updates/information/news etc if it deems to be necessary.

    Thank You

    To Top